← Back to companies
Latigo Biotherapeutics
0 open
Thousand Oaks, California, United StatesFounded 201852+ employeesGrowth raisedGrowthPrivate
Last round: series b · $150M · Mar 2025(3 rounds total)
Backed by(14 investors)
Foresite Capital5AM VenturesWestlake Village BioPartnersBlue OwlCorner VenturesCormorant Asset ManagementAccess BiotechnologyRock Springs CapitalAlexandria Venture InvestmentsUPMC EnterprisesDeep Track CapitalQatar Investment Authority
Latigo Biotherapeutics is a private clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo is supported by leading investors, including Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital. Latigo’s lead program is LTG-001, an oral, selective Nav1.8 inhibitor in development to treat acute pain.
Open Positions at Latigo Biotherapeutics (0 Jobs)
No open positions at the moment.
Browse All JobsReady to start your space career at Latigo Biotherapeutics?
